Comment from CURE SYNGAP1

Summary: CURE SYNGAP1, an advocacy organization for SYNGAP1-related disorders, supports the Haystack Project's petition to modernize rare disease drug development frameworks. They argue that the FDA should integrate disease-specific endpoints, real-world evidence, and alternative study designs to better address the unique challenges of rare diseases like SYNGAP1.